Money is an economic unit that functions as a tender of exchange for transactional purposes in an economy. But what happens to that concept when the 10-year U.S. Treasury rate diverges from the Fed’s current rate? Are stimulus cheques and capital fabrication enough to suppress yields? Is hyper-inflation already here? Are cryptocurrency and Bitcoin (BTC) valuations evidence of deteriorating confidence in central banks to keep the inflationary boogie man under wraps? Stay tuned as we discuss the moral hazard in today’s “money” and what the future of money has in store.
Midas Letter RAW is the irreverent/intelligent show about investing for the little guy. A former stockbroker and reformed accountant, Ed Milewski, brings his expert but off-beat technical chart observations into focus. At the same time, investment writer James West offers plain language critique of the machinations, shenanigans, and subterfuge foisted on retail investors by the institutions we call capital markets.
We have two exclusive interviews on deck in today’s episode:
1. Emerald Health Pharmaceuticals [not to be confused with Emerald Health Therapeutics Inc (CVE:EMH) (OTCMKTS:EMHTF) (FRA:TBD) – although both are owned by Emerald Health Sciences.] – a science-based company that uses the unique convergence of science, biology, and cannabis molecules like Cannabidiol (CBD) and Cannabigerol (CBG) to create new molecules – which can elicit beneficial effects (that CBD doesn’t) to potentially treat so-far incurable diseases.
Emerald is currently doing a Regulation A raise (which closes Sunday, March 28, 2021, at midnight) where people can invest in the private company. See here to see the CEO explain.
2. Charles Taerk, Faircourt Asset Management CEO & Ninepoint Alternative Health Fund Manager – a manager with his finger on the pulse of cannabis investing (proved by his funds’ stellar financial performance). He makes a strong case as to why the U.S. cannabis multi-state operators (MSO) have a significant advantage over Canadian licensed producers (LP). We couldn’t agree more with his thesis, and we think this interview will provide a lot of thought-provoking value to our weed stock audience.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment…